Adjuvant Immunotherapy Best for ctDNA+ Bladder Cancer
Copyright policy )Adjuvant Immunotherapy Best for ctDNA+ Bladder Cancer
Abstract A liquid biopsy may help identify patients with operable urothelial cancer who stand to benefit from adjuvant immunotherapy. In the IMvigor010 study, patients who tested positive for circulating tumor DNA showed improvement in disease-free survival and overall survival if they received adjuvant atezolizumab instead of observation.
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
citations
Citations provided by BIP!
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Citations provided by BIP!popularityPopularity provided by BIP!
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Popularity provided by BIP! 0
Average
Average
Average
This action will publish the selected files and record in Zenodo. Are you sure you want to proceed?